| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G Chouinard, W Goodman, J Greist, M Jenike, S Rasmussen, K White, E Hackett, M Gaffney, P A Bic. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology bulletin. vol 26. issue 3. 1991-02-26. PMID:2274626. |
results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. |
1991-02-26 |
2023-08-11 |
Not clear |
| G Chouinard, W Goodman, J Greist, M Jenike, S Rasmussen, K White, E Hackett, M Gaffney, P A Bic. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology bulletin. vol 26. issue 3. 1991-02-26. PMID:2274626. |
eighty-seven patients with a dsm-iii diagnosis of obsessive-compulsive disorder (ocd) without depression were entered into a double-blind, placebo-controlled study of the efficacy of sertraline, a new serotonin uptake inhibitor. |
1991-02-26 |
2023-08-11 |
Not clear |
| M T Pato, T A Pigott, J L Hill, G N Grover, S Bernstein, D L Murph. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. The American journal of psychiatry. vol 148. issue 1. 1991-01-28. PMID:1984696. |
eighteen outpatients with obsessive-compulsive disorder were treated with either buspirone, a partial serotonin agonist, or clomipramine, a serotonin uptake inhibitor, in a double-blind, random-assignment study. |
1991-01-28 |
2023-08-11 |
Not clear |
| M J Kruesi, S Swedo, H Leonard, D R Rubinow, J L Rapopor. CSF somatostatin in childhood psychiatric disorders: a preliminary investigation. Psychiatry research. vol 33. issue 3. 1991-01-03. PMID:1700858. |
somatostatin, a peptide which stimulates serotonin release and inhibits growth hormone release, was measured in the cerebrospinal fluid (csf) of 10 children with disruptive behavior disorders and in 10 age-, sex-, and race-matched pairs of obsessive-compulsive disorder patients. |
1991-01-03 |
2023-08-11 |
Not clear |
| R S Kahn, O Kalus, S Wetzler, W Cahn, G M Asnis, H M van Praa. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry research. vol 33. issue 2. 1991-01-03. PMID:2243896. |
the serotonin (5ht) agonist, m-chlorophenylpiperazine (mcpp), has been used as a challenge agent to assess central 5ht receptor sensitivity in normal subjects and patients with panic disorder, obsessive-compulsive disorder, and major depression. |
1991-01-03 |
2023-08-11 |
human |
| S A Montgomery, N A Fineberg, D Montgomer. [Biological treatments in obsessive-compulsive disorder]. L'Encephale. vol 16 Spec No. 1990-11-21. PMID:2209492. |
obsessive-compulsive disorder (ocd) is emerging very clearly as a serotonin specific illness. |
1990-11-21 |
2023-08-11 |
Not clear |
| C J Gouret, R Porsolt, J G Wettstein, A Puech, C Soulard, X Pascaud, J L Junie. Biochemical and pharmacological evaluation of the novel antidepressant and serotonin uptake inhibitor 2-(3,4-Dichlorobenzyl)-2-dimethylamino-1-propanol hydrochloride. Arzneimittel-Forschung. vol 40. issue 6. 1990-10-09. PMID:2168703. |
jo 1017 may have a potential clinical utility both in the treatment of depression and for indications where serotonin transmission is involved, e.g., anxiety, panic attack, obsessive compulsive disorder, obesity and alcohol consumption. |
1990-10-09 |
2023-08-11 |
mouse |
| B Bastani, J F Nash, H Y Meltze. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Archives of general psychiatry. vol 47. issue 9. 1990-10-03. PMID:2203327. |
prolactin and cortisol responses to mk-212, a serotonin agonist, in obsessive-compulsive disorder. |
1990-10-03 |
2023-08-11 |
Not clear |
| B Bastani, J F Nash, H Y Meltze. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Archives of general psychiatry. vol 47. issue 9. 1990-10-03. PMID:2203327. |
to examine further the serotoninergic system in obsessive-compulsive disorder (ocd), the plasma concentrations of cortisol and prolactin and the behavioral responses after oral administration of mk-212 (6-chloro-2-[1-piperazinyl]-pyrazine), a serotonin agonist, and placebo were studied in 17 patients with ocd and nine normal controls. |
1990-10-03 |
2023-08-11 |
Not clear |
| M A Jenike, S Hyman, L Baer, A Holland, W E Minichiello, L Buttolph, P Summergrad, R Seymour, J Ricciard. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. The American journal of psychiatry. vol 147. issue 9. 1990-09-14. PMID:2143637. |
thirty-eight patients with primary obsessive-compulsive disorder participated in a 10-week, double-blind, placebo-controlled trial of the potent, selective serotonin reuptake inhibitor fluvoxamine. |
1990-09-14 |
2023-08-11 |
Not clear |
| M A Jenike, S Hyman, L Baer, A Holland, W E Minichiello, L Buttolph, P Summergrad, R Seymour, J Ricciard. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. The American journal of psychiatry. vol 147. issue 9. 1990-09-14. PMID:2143637. |
these data lend only partial support to a serotonin hypothesis of obsessive-compulsive disorder. |
1990-09-14 |
2023-08-11 |
Not clear |
| J T Winslow, T R Inse. Neurobiology of obsessive compulsive disorder: a possible role for serotonin. The Journal of clinical psychiatry. vol 51 Suppl. 1990-09-12. PMID:2199432. |
neurobiology of obsessive compulsive disorder: a possible role for serotonin. |
1990-09-12 |
2023-08-11 |
Not clear |
| J T Winslow, T R Inse. Neurobiology of obsessive compulsive disorder: a possible role for serotonin. The Journal of clinical psychiatry. vol 51 Suppl. 1990-09-12. PMID:2199432. |
further evidence for the importance of serotonin in pharmacologic mediation of antiobsessional effects comes from a recent study in which administration of a serotonin antagonist (metergoline) to obsessive compulsive disorder (ocd) patients partly reversed the clinical improvement observed with clomipramine treatment. |
1990-09-12 |
2023-08-11 |
Not clear |
| W K Goodman, C J McDougle, L H Price, M A Riddle, D L Pauls, J F Leckma. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? The Journal of clinical psychiatry. vol 51 Suppl. 1990-09-12. PMID:2199433. |
beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? |
1990-09-12 |
2023-08-11 |
Not clear |
| W K Goodman, C J McDougle, L H Price, M A Riddle, D L Pauls, J F Leckma. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? The Journal of clinical psychiatry. vol 51 Suppl. 1990-09-12. PMID:2199433. |
it seems unlikely that a solitary disturbance in serotonin function can fully account for the pathophysiology of obsessive compulsive disorder. |
1990-09-12 |
2023-08-11 |
Not clear |
| M R Trimbl. Worldwide use of clomipramine. The Journal of clinical psychiatry. vol 51 Suppl. 1990-09-12. PMID:2199435. |
clomipramine, a preferential inhibitor of 5-hydroxytryptamine uptake, has proven effective in the management of depression, resistant depression, and obsessive compulsive disorder. |
1990-09-12 |
2023-08-11 |
Not clear |
| W K Goodman, L H Price, P L Delgado, J Palumbo, J H Krystal, L M Nagy, S A Rasmussen, G R Heninger, D S Charne. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of general psychiatry. vol 47. issue 6. 1990-07-09. PMID:2112374. |
specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. |
1990-07-09 |
2023-08-11 |
Not clear |
| W K Goodman, L H Price, P L Delgado, J Palumbo, J H Krystal, L M Nagy, S A Rasmussen, G R Heninger, D S Charne. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of general psychiatry. vol 47. issue 6. 1990-07-09. PMID:2112374. |
to evaluate whether serotonin reuptake inhibition is critical to the treatment of obsessive-compulsive disorder, 40 outpatients with a principal diagnosis of obsessive-compulsive disorder were randomized in a double-blind fashion to 8 weeks of treatment with either the serotonin reuptake inhibitor fluvoxamine maleate (n = 21) or the norepinephrine reuptake inhibitor desipramine hydrochloride (n = 19). |
1990-07-09 |
2023-08-11 |
Not clear |
| W K Goodman, L H Price, P L Delgado, J Palumbo, J H Krystal, L M Nagy, S A Rasmussen, G R Heninger, D S Charne. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Archives of general psychiatry. vol 47. issue 6. 1990-07-09. PMID:2112374. |
it is hypothesized that the mechanism of action of serotonin reuptake inhibitors in obsessive-compulsive disorder may be related to chronic treatment-induced adaptive changes in presynaptic serotonin receptor function (eg, autoreceptor desensitization) and/or indirect influences on dopaminergic function (eg, in the basal ganglia). |
1990-07-09 |
2023-08-11 |
Not clear |
| D L Murphy, T A Pigot. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. The Journal of clinical psychiatry. vol 51 Suppl. 1990-05-11. PMID:2139026. |
a comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. |
1990-05-11 |
2023-08-11 |
Not clear |